Q3 EPS Forecast for Candel Therapeutics Decreased by Analyst

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at Brookline Capital Markets decreased their Q3 2026 EPS estimates for Candel Therapeutics in a research note issued on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings of ($0.33) per share for the quarter, down from their previous estimate of ($0.26). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.30) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q4 2026 earnings at ($0.32) EPS.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28).

Several other equities research analysts have also commented on the company. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Stifel Nicolaus assumed coverage on Candel Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $22.00 target price on the stock. Bank of America boosted their price target on Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.29.

Candel Therapeutics Trading Down 0.9%

Shares of Candel Therapeutics stock opened at $12.05 on Monday. The company’s fifty day simple moving average is $9.82 and its 200-day simple moving average is $7.50. The stock has a market capitalization of $922.05 million, a PE ratio of -8.55 and a beta of -0.51. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $12.48. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new stake in Candel Therapeutics during the first quarter valued at about $845,000. Halter Ferguson Financial Inc. boosted its stake in shares of Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after acquiring an additional 155,996 shares during the period. Walleye Capital LLC bought a new position in shares of Candel Therapeutics in the second quarter worth about $419,000. Renaissance Technologies LLC purchased a new stake in shares of Candel Therapeutics during the first quarter worth about $63,000. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of Candel Therapeutics during the first quarter worth about $178,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Insider Buying and Selling

In other news, insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00. Following the sale, the chief technology officer owned 83,865 shares in the company, valued at $840,327.30. The trade was a 7.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 14.30% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.